2024-12-14 10:32:23
Xray, an important partner of Yizhizhuang, officially announced a strategic cooperation with Google. According to Yizhizhuang, at the Android XR conference held in new york, Google officially announced a strategic cooperation with Xray to jointly build the Android XR ecosystem. This cooperation not only highlights XREAL's position as the world's largest manufacturer of AR glasses, but also marks a new stage of accelerated popularization of XR industry. It is noteworthy that Lingyizhi, as a long-term strategic partner of XREAL, provides key components and assembly services for XREAL AR glasses.Hongrun Construction established a commercial management company in Wuxi. According to the enterprise search APP, Wuxi Hongrun Commercial Management Co., Ltd. was recently established. The legal representative is Jin Zhenjun, with a registered capital of 1 million yuan. Its business scope includes: commercial complex management services; Property management; Real estate broker, etc. Enterprise investigation shows that the company is wholly owned by Hongrun Construction.Xray, an important partner of Yizhizhuang, officially announced a strategic cooperation with Google. According to Yizhizhuang, at the Android XR conference held in new york, Google officially announced a strategic cooperation with Xray to jointly build the Android XR ecosystem. This cooperation not only highlights XREAL's position as the world's largest manufacturer of AR glasses, but also marks a new stage of accelerated popularization of XR industry. It is noteworthy that Lingyizhi, as a long-term strategic partner of XREAL, provides key components and assembly services for XREAL AR glasses.
Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.Microsoft: The latest small language model PHI-4, which is specially used for complex reasoning, is introduced.It is reported that the Trump consultant is seeking to reduce or cancel the banking regulator. It is reported that the Trump transition team has begun to explore ways to significantly reduce, merge or even cancel the banking regulator. According to people familiar with the matter, Trump's advisers and potential candidates who may be nominated to lead the banking regulator discussed plans to merge or reorganize major banking regulators, including the Federal Deposit Insurance Corporation, the Office of the Comptroller of the Currency and the Federal Reserve.
FTSE China A50 index futures opened 0.80% lower, and closed down 0.89% in the last session.The turnover of Shanghai and Shenzhen stock markets exceeded 500 billion.The Hang Seng Index and Hang Seng Technology Index both fell more than 1%.
Strategy guide 12-14
Strategy guide
Strategy guide
12-14
Strategy guide
12-14
Strategy guide 12-14
Strategy guide
12-14
Strategy guide 12-14